This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
TheStreet Open House

Gilead Wows With New Hep C Data, Boxing Out Poor 2012 Guidance

Updated with stock price.

FOSTER CITY, Calif. ( TheStreet) -- Gilead Sciences (GILD) surprised investors Thursday night with exciting new data from its lead hepatitis C drug that overshadowed a disappointing fourth-quarter earnings and weaker-than-expected guidance for the coming year.

Gilead shares are up 9% to $54.07 in Friday afternoon trading.

On Gilead's quarterly conference call, the company's research chief disclosed that all genotype 1 hepatitis C patients treated with the experimental pill GS-7977 plus ribavirin had no evidence of the virus after four weeks of treatment.

These new data are early but impressive because they suggest that a two-drug combination of pills may be potent enough to cure patients with genotype 1 hepatitis C, which is the most common form of the disease in the United States.

Gilead acquired rights to GS-7977 (formerly PSI-7977) through the $11 billion acquisition of Pharmasset. The deal pushed Gilead to the front of the pack of companies seeking to develop an all-oral regimen for hepatitis C that does away with the need for weekly injections. Bristol-Myers Squibb (BMY) is paying $2.5 billion to acquire Inhibitex (INHX) for the same reason.

Further data supporting GS-7977's ability to definitively cure these genotype 1 hepatitis C patients will be presented at the Conference on Retroviruses and Opportunistic Infections (CROI) being held March 5-8 in Seattle.

Gilead's new GS-7977 data announced Thursday night come from a phase II study known as Electron first started by Pharmasset. In this particular arm of the study, 35 patients with genotype 1 hepatitis C (25 treatment-naïve patients and 10 who failed to respond to previous therapy) were treated with GS-7977 plus ribavirin.

After four weeks of this two-drug oral therapy, 100% of patients achieved what is known as a "rapid viral response" or RVR, meaning that the virus could no longer be detected in their blood. RVR is an early and promising signal that drugs are working but it is not definitive proof of a hepatitis C cure. Patients are only deemed cured of hepatitis C -- a sustained virologic response or SVR -- if they have no evidence of the virus in their system 12 weeks after stopping treatment.

At the upcoming CROI meeting Gilead will present further results on some of these 35 patients, specifically showing how many have undetectable virus four weeks after treatment with GS-7977 plus ribavirin ended.

1 of 2

Select the service that is right for you!

COMPARE ALL SERVICES
Action Alerts PLUS
Try it NOW

Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
  • Weekly roundups
TheStreet Quant Ratings
Try it NOW
Only $49.95/yr

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
  • Upgrade/downgrade alerts
Stocks Under $10
Try it NOW

David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
  • Weekly roundups
Dividend Stock Advisor
Try it NOW

Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Alerts when market news affect the portfolio
  • Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
Real Money Pro
Try it NOW

All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.

Product Features:
  • Real Money + Doug Kass Plus 15 more Wall Street Pros
  • Intraday commentary & news
  • Ultra-actionable trading ideas
Options Profits
Try it NOW

Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • 100+ monthly options trading ideas
  • Actionable options commentary & news
  • Real-time trading community
  • Options TV
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!
DOW 17,279.74 +13.75 0.08%
S&P 500 2,010.40 -0.96 -0.05%
NASDAQ 4,579.7890 -13.6380 -0.30%

Brokerage Partners

Rates from Bankrate.com

  • Mortgage
  • Credit Cards
  • Auto

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs